Who are Cyclosporine 0.09% Ophthalmic Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elidel, Prograf, Sandimmune, Sandimmune, CYCLOSPORINE, XR-tacrolimus QD + MMF BID then MMF QD.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclosporine-0-09-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cyclosporine 0.09% Ophthalmic Solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclosporine 0.09% Ophthalmic Solution (Cyclosporine 0.09% Ophthalmic Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor. Area: Ophthalmology.

marketed Calcineurin inhibitor Calcineurin (protein phosphatase 2B) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Cyclosporine 0.09% Ophthalmic Solution (Cyclosporine 0.09% Ophthalmic Solution) — Center for Ophthalmic and Vision Research, LLC. Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclosporine 0.09% Ophthalmic Solution TARGET	Cyclosporine 0.09% Ophthalmic Solution	Center for Ophthalmic and Vision Research, LLC	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)
Elidel	PIMECROLIMUS	Bausch Health	marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	Peptidyl-prolyl cis-trans isomerase FKBP1A	2001-01-01
Prograf	TACROLIMUS	Astellas Pharma	marketed	Calcineurin Inhibitor Immunosuppressant	Interferon gamma	1994-01-01
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
Sandimmune	Ciclosporin	Novartis	marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	1983-01-01
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
XR-tacrolimus QD + MMF BID then MMF QD	XR-tacrolimus QD + MMF BID then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2027-11-03 — Sandimmune · 8298568 · US
2028-05-30 — Prograf · 9549918 · Formulation · US
2028-05-30 — Prograf · 10166190 · Formulation · US
2028-05-30 — Prograf · 11419823 · Formulation · US
2028-05-30 — Prograf · 12403095 · Formulation · US
2028-05-30 — Prograf · 11123331 · Method of Use · US
2028-05-30 — Prograf · 11110081 · Method of Use · US
2028-05-30 — Prograf · 12083103 · Method of Use · US
2028-05-30 — Prograf · 10864199 · Method of Use · US
2028-08-30 — Prograf · 8664239 · Method of Use · US
2028-08-30 — Prograf · 8685998 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · US
2032-04-16 — Sandimmune · 8561859 · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · US
2033-08-23 — Sandimmune · 8980839 · US
2033-08-23 — Sandimmune · 10441630 · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · US

Sponsor landscape (Calcineurin inhibitor class)

Novartis · 4 drugs in this class
Astellas Pharma Inc · 4 drugs in this class
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · 4 drugs in this class
University of Cincinnati · 3 drugs in this class
Allergan · 3 drugs in this class
Astellas Pharma China, Inc. · 3 drugs in this class
Novaliq GmbH · 3 drugs in this class
Hoffmann-La Roche · 3 drugs in this class
LEO Pharma · 3 drugs in this class
Santen SAS · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclosporine 0.09% Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclosporine-0-09-ophthalmic-solution. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab